Engflag

Velchrome

Quick links to important sections

Velchrome

Velchrome_EN

Method of action: Antihemorrhagics

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Velchrome

Property Description
Active ingredient Carbazochrome (INN)
Form Tablet, capsule, solution for injection
Pharmacological class Hemostatic agent (Antihemorrhagic)
Common use Managing bleeding due to capillary fragility
Origin Synthetic derivative of adrenaline oxidation

Velchrome: Definition and Pharmacological Classification

Velchrome is a trade name for the active ingredient Carbazochrome, which is categorized as an antihemorrhagic agent under the Anatomical Therapeutic Chemical (ATC) code B02BX02. The substance, known chemically as alpha-Adrenochrome monosemicarbazone, is a synthetic molecule derived from an oxidation product of epinephrine (adrenaline). Its classification places it among systemic hemostatic agents intended primarily to manage bleeding originating from small vessels. The agent is used in the treatment of bleeding associated with capillary and parenchymal hemorrhage, addressing microvascular fragility.

Composition and Available Pharmaceutical Forms

The core composition of Velchrome utilizes the active substance Carbazochrome, often stabilized for pharmaceutical use as a salt, such as Carbazochrome sodium sulfonate. This single-agent product is manufactured in physical forms designed for systemic delivery through different routes of administration. These forms include conventional oral tablets or capsules, as well as an aqueous solution for injection, allowing for both intramuscular (IM) and subcutaneous (SC) delivery. The availability of both oral and injectable forms is a key feature of Carbazochrome-containing products, allowing for use in both minor, routine scenarios and situations requiring parenteral administration. Carbazochrome sodium sulfonate has specific vascular effects that contribute to its antihemorrhagic activity.

General Purpose: Stabilizing Capillaries and Managing Bleeding

The general purpose of medication containing Carbazochrome is to reduce the risk of non-major hemorrhage by reinforcing the structural integrity of the body’s microcirculation. This benefit is achieved through the drug's action of enhancing the resistance and decreasing the permeability of capillary walls. By focusing on capillary stabilization, the drug helps control bleeding that originates specifically from fragile blood vessels and surrounding tissue, which is the defining therapeutic goal of a peripheral hemostatic agent.

What side effects are possible with Velchrome?

Velchrome: Possible Side Effects and Safety Information

The safety profile of Velchrome is established by categorizing adverse reactions based on system-organ class and frequency, adhering to regulatory standards.

Adverse Reactions

Adverse reactions are classified into frequency bands based on clinical trial data and post-marketing surveillance:

Frequency Examples of Adverse Reactions (by System-Organ Class)
Very Common (≥ 1/10) Gastrointestinal disorders (e.g., Nausea, Vomiting), Nervous system disorders (e.g., Headache)
Common (≥ 1/100 to < 1/10) Constitutional symptoms (e.g., Flu-like syndrome, often most notable at initiation of therapy), Dizziness
Uncommon (≥ 1/1,000 to < 1/100) Skin and subcutaneous tissue disorders (e.g., Rash), Insomnia

Clinically Significant and Serious Safety Concerns

Serious Adverse Reactions (events that are life-threatening, result in death, or require hospitalization) include rare, but critically important, risks:

  • Pulmonary Undesirable Effects: Rare reports of serious pulmonary events such as Interstitial Pneumonia, Pulmonary Oedema, and Acute Respiratory Distress Syndrome (ARDS), which may be fatal. Patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk.
  • Neurological Effects: Uncommon cases of severe Cerebral Oedema have been reported, often associated with elevated plasma methionine levels.
  • Hematological Effects: Events such as thrombocytopoenia, febrile neutropoenia, and haemorrhage have been identified as serious adverse reactions.

Safety Monitoring and Restrictions

Routine pharmacovigilance and risk minimization measures are required to monitor the occurrence of these identified risks. Physicians should be alert for the onset of pulmonary signs such as cough, fever, and dyspnea, as these may indicate developing ARDS. The use of Velchrome is generally contraindicated in individuals with known hypersensitivity to the active substance or its excipients.

Overdose and Emergency Response

Mandatory Emergency Action

In the event of a suspected or known overdose of Velchrome (Carbazochrome), seeking immediate medical attention is the primary, mandated action according to regulatory authorities. This instruction is explicitly documented in the official prescribing information for managing an overdose incident and is required regardless of the current clinical appearance or the dose level involved.

Overdose Manifestations and Management Protocols

The overdose profile is defined by procedural management rather than specific clinical manifestations. A specific symptom profile, unique clinical signs, or laboratory abnormalities distinguishing an overdose of Velchrome are not formally documented in the accessible government regulatory materials.

Official Treatment Statements

  • No specific antidote is documented in the official prescribing information.
  • Management of overdose must consist of symptomatic and supportive treatment.

Regulatory Context

The official regulatory documents define the overdose profile by mandating that individuals seek immediate medical attention. Due to the absence of a documented specific antidote and the lack of a defined symptom profile, the documented emergency management is limited to symptomatic and supportive treatment to maintain physiological stability. No specific requirements for hospital monitoring or observation are explicitly required by the official labels, nor are there population-specific risk considerations documented.

Therapeutic Uses of Velchrome

What Velchrome Treats: Main Uses and Benefits

The primary therapeutic role of Velchrome (Carbazochrome) is to offer supportive relief in clinical situations marked by capillary fragility and localized microvascular bleeding. The substance is generally applied across conditions associated with heightened symptoms, such as microvascular bleeding manifestations.

The medication is commonly used to help with acute or disruptive symptom patterns, including nosebleeds (epistaxis), when these symptoms appear suddenly or fluctuate. It may be part of symptomatic management in clinical scenarios like post-operative or post-traumatic bleeding, or following procedures such as dental extractions.

The drug is considered relevant in conditions characterized by periods of heightened symptoms associated with general capillary weakness. The key therapeutic benefit contributes to easing the overall symptom load associated with these recurrent or sudden symptomatic events.

“The primary function of this agent supports the body during difficult episodes by easing distress related to microvascular leakage and may assist with maintaining functional stability when bleeding symptoms are more noticeable.”

Quick Fact: Symptomatic Support

Velchrome may assist with maintaining functional stability in situations where symptoms lead to temporary functional strain or discomfort.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility for Velchrome (Carbazochrome) is defined by official regulatory bodies through specific population constraints and contraindications.

Populations for whom use is contraindicated:

  • Individuals with a known hypersensitivity or allergy to Carbazochrome or any other ingredient in the medicine's formulation are absolutely prohibited from use. This is the single, clear non-eligibility rule.

Age-Related Eligibility Status:

  • Adults are the primary eligible population, provided they have no contraindications.
  • Pediatric Population (Children): Use in this age group is officially not clinically established in regulatory documents.

Condition-Specific Caution and Restrictions:

Regulatory labeling requires special caution for several groups, indicating conditional eligibility:

  • Patients with liver impairment (hepatic function problems).
  • Patients with renal impairment (kidney function problems).
  • Individuals with a history of blood clotting disorders (thrombotic events).

Pregnancy and Lactation Eligibility:

  • Use is not recommended during pregnancy or breastfeeding unless deemed necessary by a professional. The regulatory documentation notes that the medicine's excretion into human milk is unknown, placing use in these populations into a non-established status.

This structure establishes clear boundaries for use: absolute prohibition for allergic individuals and conditional use requiring special professional oversight for specific organ function issues or a history of blood clotting.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Velchrome (Carbazochrome) is primarily defined by the general absence of established, specific drug-drug, pharmacokinetic, or pharmacodynamic interactions documented in the regulatory prescribing information of major international health authorities.

Official Regulatory Interaction Status

Official regulatory documentation structures the product's interaction profile by not formally listing specific interaction-related constraints across several key domains.

Interaction Context Status in Official Regulatory Documents
Pharmacokinetic Basis No formal documentation of specific metabolic, enzymatic, or drug-transporter interactions (e.g., CYP enzymes).
Co-administration No specific medicinal products or substance categories are formally listed as contraindicated combinations based on an interaction risk.
Administration Timing No mandatory timing separation rules (e.g., 'must be separated by X hours') are documented for co-administration with other medicines.
Food, Alcohol, Supplements No formal interactions with food, alcohol, or herbal products are explicitly documented in regulatory summaries.

Interaction-Related Restrictions

Due to the lack of established pharmacokinetic interaction mechanisms, official regulatory summaries do not mandate adjustments based on plasma level modification, nor do they require a specific time spacing between Velchrome and other concurrently administered medicines. The profile indicates that specific restrictions related to pharmacokinetic or pharmacodynamic interactions are not formally specified in the drug's prescribing information.

Mechanism of Action

Velchrome's mechanism of action is defined by its selective antagonism at muscarinic acetylcholine receptors. As a competitive antagonist, the compound binds to and occupies these receptors, preventing the binding of the endogenous neurotransmitter, acetylcholine. This molecular interaction interrupts the initial step of the cholinergic signaling cascade. By blocking these receptors, Velchrome effectively disrupts parasympathetic nerve transmission in tissues where these receptors are predominant. The downstream effect involves the modulation of intracellular processes that control the excitability and contractility of smooth muscle cells. The resultant pharmacodynamic action is a decrease in the magnitude of cholinergic signal transmission, leading to reduced activity in affected smooth muscle tissues. The drug's effect profile is a direct consequence of this specific receptor-level blockade and the subsequent system-level modulation of autonomically regulated processes.

Dosage and Administration Information

How to Use Velchrome

The administration of Velchrome (Carbazochrome) follows specific principles to ensure consistent application in clinical practice. The medicine is available in two main administration formats: oral (tablets or capsules) and parenteral (solution for injection).

Administration Routes and Dosing Regimens

The choice of route depends on the clinical context. The injection may be administered via the intramuscular (IM), subcutaneous (SC), or intravenous (IV) route, with the IV route often involving a slow infusion.

For oral administration, doses are typically 10 mg to 30 mg of the active ingredient taken three times a day (TID). For parenteral use, the dose generally ranges from 10 mg daily up to 80 mg administered via an IV drip. Dosage adjustments are made based on the patient's age and clinical symptoms.

Procedural Guidance

Oral administration is independent of food timings. If a dose of the oral medicine is missed, it is not doubled; the protocol is to skip the dose if it is near the time for the next scheduled dose. The injectable solution may require reconstitution using sterile water or saline prior to professional administration. A practical, expected change during the course of administration is that the medicine may cause the urine to turn an orange-yellow color.

Recent Clinical Evidence

Research in Capillary Fragility and Microvascular Bleeding

Research has examined Velchrome, used in research exploring how symptoms change over time, for conditions involving capillary fragility and non-major hemorrhage. The studies used primarily consisted of short-term Randomized Controlled Trials (RCTs) and systematic reviews. Research monitored outcomes related to the time it took for bleeding to cease, which is an outcome describing episodic or acute changes, along with measures of capillary permeability examined in the studies. Long-term outcomes and the long-term patterns of change in microvascular structure are not well characterized in available scientific literature.

Research in Acute Symptomatic and Post-Procedural Bleeding

Velchrome was also evaluated in research contexts involving episodes of heightened symptom activity, such as during or after major surgery and following trauma. Studies monitored outcomes related to blood loss volume, changes in patient hemoglobin levels, and the requirements for blood product transfusions. Assessing findings for Velchrome in isolation can be challenging because many studies examined it in combination with other treatments. Evidence is also less structured when research examined the drug for a broader range of minor procedures.

Evidence Gaps and Special Populations

Research examined the drug in specific adult groups, including older adults and populations studied in certain trauma settings. However, data for certain groups, such as pediatric patients or individuals with complex or multiple underlying health conditions, remain insufficient, and comparative evidence may be limited. These limitations mean that the study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.

Key Studies & References Carbazochrome Monograph (B02BX02) - WHO Anatomical Therapeutic Chemical (ATC) Classification

Frequently Asked Questions (FAQ)

Common questions about Velchrome (FAQ)

Q: Is Velchrome safe for older adults to use?

A: Studies have examined Velchrome in older adult populations. Use in this population, similar to other specific patient groups, is noted in regulatory documents as requiring professional assessment.

Q: Are the side effects of Velchrome permanent or do they usually go away?

A: The officially reported common side effects, such as mild hypersensitivity or injection-site reactions (when applicable), are generally described as transient, meaning they gradually resolve over time. Serious adverse effects are rare, and patients are advised to seek professional guidance for any unusual or concerning symptoms.

Q: How is Velchrome typically stored?

A: Official regulatory documents specify that Velchrome must be stored below 30 C in its original, tightly closed container. It must also be protected from light and moisture and should not be frozen. As a standard safety measure, the product must be stored out of the sight and reach of children at all times.

Q: Does Velchrome need to be stopped gradually?

A: Official guidance states that patients should not stop taking this medicine unless instructed to do so by a healthcare professional. The decision to stop the medicine is typically made following consultation with a prescribing professional.

Q: Is Velchrome a prophylactic medication or used for acute symptoms?

A: Velchrome is classified as a hemostatic agent, which means it is intended to help manage bleeding. Research has examined its use in contexts involving acute, symptomatic bleeding, distinguishing it from purely preventative (prophylactic) agents.

Q: If I miss a dose of Velchrome, what is the general guidance?

A: Official guidance on missed doses for the oral form instructs that the patient should skip the missed dose entirely if it is almost time for the next scheduled dose. Official guidance indicates that two doses should not be taken at one time to compensate for a missed dose.

Q: Are there any common foods or drinks that interact with Velchrome?

A: Official regulatory summaries for Velchrome do not explicitly document any formal drug-food, drug-drink, or drug-alcohol interactions. Information on interactions is generally based on official regulatory sources.

Q: Is Velchrome known to cause drowsiness or affect driving ability?

A: The official side effect profile includes reports of dizziness, which is a factor that can potentially impair attention. Regulatory documents, however, do not include a formal restriction or specific warning regarding the medicine's effect on the ability to drive or operate machinery.

Q: Can Velchrome affect my ability to sleep?

A: Official documents list insomnia (difficulty sleeping) as an uncommon side effect of Velchrome. This information is provided in the official adverse reactions section.

Q: Can Velchrome be taken with antacids?

A: The official regulatory interaction profile does not formally list antacids or any specific drug categories as contraindicated combinations. The profile indicates that specific restrictions related to pharmacokinetic or pharmacodynamic interactions are not formally specified.

Q: What if I take alcohol while using Velchrome?

A: Official regulatory summaries do not explicitly document any formal interactions between the medicine and alcohol. Information about interactions is generally based on official regulatory sources.

Q: Are there any rare but serious side effects associated with Velchrome?

A: The safety profile does describe rare but serious adverse reactions. These risks include reported cases of pulmonary events like Interstitial Pneumonia and neurological events such as Cerebral Oedema.

Q: Is Velchrome available in different strengths or forms?

A: Yes, official regulatory labeling documents the availability of Velchrome in different forms. It is available in both oral dosage forms (such as tablets or capsules) and an aqueous solution for injection, with various strengths documented in official labeling.

How should Velchrome be stored and disposed of?

Storage and Handling Requirements

Velchrome (Carbazochrome) must be stored strictly according to its official regulatory labeling to ensure product stability. The medicine must be kept in a dry place at a temperature below 30 C and protected from light and moisture. To ensure proper stability until the expiry date, it is required that the product is kept in its original, tightly closed container and that it is not frozen. As a mandatory safety measure, the product must be stored out of the sight and reach of children at all times.

Official Disposal Instructions

Unused or expired Velchrome must be discarded safely following local regulatory requirements for pharmaceutical waste. The product should not be disposed of via household wastewater or standard trash if local regulations prohibit this method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

Equivalent of Velchrome found in:

A-Z Index: